Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...
Hosted on MSN39m
Astra Invests $3.5 Billion in US as Cancer Sales RiseAstra and partner Daiichi Sankyo Co Ltd said Tuesday a previously submitted application to the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback